- Home
- PEG vs ARGX Comparison
PEG vs ARGX Comparison
Compare PEG & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEG
- ARGX
- Stock Information
- Founded
- PEG 1903
- ARGX 2008
- Country
- PEG United States
- ARGX Netherlands
- Employees
- PEG N/A
- ARGX N/A
- Industry
- PEG Power Generation
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEG Utilities
- ARGX Health Care
- Exchange
- PEG Nasdaq
- ARGX Nasdaq
- Market Cap
- PEG 46.0B
- ARGX 37.3B
- IPO Year
- PEG N/A
- ARGX 2017
- Fundamental
- Price
- PEG $82.97
- ARGX $624.18
- Analyst Decision
- PEG Buy
- ARGX Strong Buy
- Analyst Count
- PEG 13
- ARGX 21
- Target Price
- PEG $87.75
- ARGX $630.42
- AVG Volume (30 Days)
- PEG 2.4M
- ARGX 293.9K
- Earning Date
- PEG 11-04-2024
- ARGX 10-31-2024
- Dividend Yield
- PEG 2.85%
- ARGX N/A
- EPS Growth
- PEG N/A
- ARGX N/A
- EPS
- PEG 4.07
- ARGX N/A
- Revenue
- PEG $10,430,000,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- PEG N/A
- ARGX $61.99
- Revenue Next Year
- PEG $5.86
- ARGX $42.48
- P/E Ratio
- PEG $20.69
- ARGX N/A
- Revenue Growth
- PEG N/A
- ARGX 85.56
- 52 Week Low
- PEG $56.85
- ARGX $327.73
- 52 Week High
- PEG $95.22
- ARGX $644.97
- Technical
- Relative Strength Index (RSI)
- PEG 30.97
- ARGX 58.62
- Support Level
- PEG $85.30
- ARGX $602.44
- Resistance Level
- PEG $87.06
- ARGX $644.97
- Average True Range (ATR)
- PEG 1.61
- ARGX 13.22
- MACD
- PEG -0.87
- ARGX -0.01
- Stochastic Oscillator
- PEG 0.12
- ARGX 51.12
About PEG Public Service Enterprise Group Incorporated
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and other nonregulated businesses such as nuclear power generation and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.